ABSTRACT: 5-aminosalicylic acid (5-ASA) preparations were anticipated to be and generally are better coleratec.l than sulphasalazine. Minor side effects such as headache, dizziness, abdominal pain and nausea do occur but are not more frequent than in placebo-treated patients. Approximately l 0% of patients thought to be allergic to sulphasalazinc are also allergic to 5-ASA. An idiosyncratic reaction with worsening of symptoms can occur. Diarrhea is more common with olsalazine, and it is due to the effect of olsalazme itself on the small bowel. not the 5-ASA component. There are case reports of pancreatitts, pericarc.litts and hronchospasm, rctmsternal chest pain, mile.I neutropenia, nephrotic syndrome and hair loss associated with 5-ASA treatment. Patients with oligospermia due to sulphasalazme have improved when switched to 5-ASA. 5-ASA enemas can cause local 1rntation or other effects resulting from 
S ULPIIASALAZINE WAS CREATED IN
the 19 30s hy Svarrz for the treatment of rheumatoid arthritis. It was hy chance that fovorahlc effects were noted in ulcerative colitis ( l ). In the early 1950s sulphasalazme was used in the Unired Stares for the treatment of ulcerauve LOIItis with good results. It hecame a, ailahle m Great Bmain 111 l 955. Since then 1t has heen shown in Gastrrnnce.rnnal controlled trials to he effective 111 rhc treatment of acute ulcerative colitis (2, 3) as well as m ma111tenancc therapy (4) (5) (6) . I lowever, su lphasalaz111e did not crnnplerely elimmare the risk of recurrent ,Htacks and a proportton o( patients could nor tolerate su lphasalazine 111 therapeutic doses ( 7) . Most of thl' sic.le effects of sulphasalmmc haw heen ascnbcd to the sulfapyndtnl' moiety ,md umclate well with sulfapyndmc serum levels (8) .
Sulphasalazine has an unusual metabolism. Only 20 10 30% of the orall} admm11>tercd Jose ,~ absorbec.l from the upper gastromtcstinal traCL (9) . A major pan of the ahsorhed sulphasal.dnc is excrerec.l m the bile without 1rnxlificarion by the liver anc.l unc.lergoes enterohepatic circulation (9) . Less than I O' Yo is ex<.:reteJ unchangc<l in urine.
Ahout 75% llf sulphasalazme reaches the colon unchangec.l, where the .1:ohllnd is ,plir hy the bacterial azo-reducrnsc enzyme mto the mernbol itcs 5-ASA and sulfapyri<line. Most of the su lfapynJme is absorbed and acctylmed, hydroxylated and conjugated wtt h glucurnnidc1, for exc retion in urine ( l 0, 11 ). The majonty of 5-ASA remains within the colon and c.an be recovered in the feces. A small part 1s nbsorhcc.l and acct ylatcd hy the colonic epithelium, liver and kidney, and excreted 111 unne. W hen 5-ASA and sulfapync.lme arc adm inistered as smglc agents orally, each is promptly ahsorhed in the proximal gastrointe,tinal tract, mernholizec.l hy the liver anc.l excreted 111 urine (10,12).
SHARMA
In 1977 1t was Jemomtratcd that 5-ASA 1s the active moiety of sulphasalazine for the treatment of ulcerative coltt1s (13 ) . This has since been confirmed (14), and led to the development of two types of agents: compounds in which sulfapyndine is replaced by another carrier molecule, considered to be less likely to produce side effects. (One ingenious structure is obalazine, where two molecules of 5-ASA are Joined by an azobond. These compounds require bacterial enzyme action to be split into the active compounds in the distal ileum and colon); and 5-ASA (mcsalaminc) with various coaring systems to retard upper gastroinrcst1nal absorption and thus minimize possible renal tox1c1Ly.
It appears reasonable to assume that the spectrum of untoward effects 1s similar for the various rnesalaminc products and that the s1Je effects caused by a new azo-compound of 5-ASA coulJ differ in certain respects from mesalamine formations.
MESALAMINE
&cause sulphasalazine was already in din1ql use with mo:.t of the side effects thL1ught to be related to the suliapyndine m01ety, 5-ASA, the active moiety, was anttc1pated to be ~afer to use and m mtroductton tl> clinical med1c111e followed a wmewhat different sequenc.:e.
Initial animal experimenb usmg 5-ASA by Calder er al (15) on rats showed nephrntox1c1ty. Smgle mtravenous mjection of 5-ASA al dosages of 1.4, 2.8 and 5.7 mM/kgcaused renal comcal necrosis in 2 3 of 60 rats, 13 of which also had associated papillary nec.:rosis. l ligher dosages tended to produce more severe les1om, but there were exceptions. As 5-ASA has molecular sunilanttes to phenacetin, rhe sporadte and mcomplere 111c1dencc of renal lesions was thought to be due to a sumlar mechanism seen with analgcsKs.
An open srudy of 5-ASA (Pentasa; Nordic Lahomtories) was perfonncd by Ra:,mussen et al (16) m 18 patients with Crohn's d1~e,1.,e unresponsive ni other dn1 gs. Oral Pemasa, 500 mg tid, was effective and was not associated with 444 any side effects. In pamcular, there was no change in the urinary sediment or 51 Cr EDT A plasma clearance. None of the other biochemical and hematological tests showed any alteration.
Since then there has been only one report of a patient who developed nephrottc syndrome after five months of treatment with mesalamine 800 mg tid ( 17). In the study by Riley et al ( 18) two of 21 patients treated with Asacol (Norwich-Eaton) 1200 mg twice daily for four weeks developed up co a twofold rise m plasma creatinme which returned to normal after discontinuamm of treatment. One further patient has been reported to have a decrease in creatinine clearance on Asacol treatment (19). This patient had previously been treated with sulphasalazine without J1fficulry. In the post marketing adverse reaction reporting of various Salofalk (lnterfalk) preparations between 1984 and 1989, using 663,608 patients/treatment cycle, only six cases of interstitial nephritis were noted (personal commumcation).
Mesalamine was initially used in patients allergic or intolerant to sulphasalazine {19-26). Approximately 85% of these patients were able to tolerate mesalamme. It appears that patients who experienced allergic and upper gastrointestinal effects while receiving sulphasalazine commonly experience a similar reaction to mesalamine (20, 21, 23, 25 ) . Leukopenia has been reported on substitution of mesalamine for sulphasalazme in a patient who haJ developed leukopenia while being treated with sulphasalazine (25). In a randomized trial rhe incidence of headache was reported to occur with sumlar frequency during treatment with mesalamine or sulphasalazine (27). Riley et al (28) noted that headache resolved during continued therapy more often in patients treated with mesalamine (80%) than in those receiving sulphasalazine (50%) and that regular headaches were more common with sulphasalazme (P<0.02). Donald et al (22) noted that two patients who were re1..e1ving Asacol 1600 mg/day and expem:nung headaches were free from headaches at a redu1..ed dlhe of 800 mg/day. Th 1s suggests that nor all of the allergic side effects or intolerance to sulphasalazme are related to the sulfapyridine component. In a recent mtemattonal randomized double-blind study comparing sulphasalazine and mesalamine the incidence of headache and ep1gastric pain was similar in the two groups, and the incidence of hypersensitivity reacuons and nausea and vom1tmg was four times more in the su lphasalazme group compared to the mesalamine group (29).
In a placebo controlled random1"ed study of oral 5-ASA, there was no sig- 
